RT Journal Article
T1 Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool.
A1 Herrero-Aguayo, Vicente
A1 Saez-Martinez, Prudencio
A1 Jimenez-Vacas, Juan M
A1 Moreno-Montilla, M Trinidad
A1 Montero-Hidalgo, Antonio J
A1 Perez-Gomez, Jesus M
A1 Lopez-Canovas, Juan L
A1 Porcel-Pastrana, Francisco
A1 Carrasco-Valiente, Julia
A1 Anglada, Francisco J
A1 Gomez-Gomez, Enrique
A1 Yubero-Serrano, Elena M
A1 Ibañez-Costa, Alejandro
A1 Herrera-Martinez, Aura D
A1 Sarmento-Cabral, Andre
A1 Gahete, Manuel D
A1 Luque, Raul M
K1 FASN
K1 PSA
K1 miR-107
K1 miRNome
K1 Non-invasive biomarker
K1 Obesity
K1 Prostate cancer
AB Prostate-specific antigen (PSA) is the gold-standard marker to screen prostate cancer (PCa) nowadays. Unfortunately, its lack of specificity and sensitivity makes the identification of novel tools to diagnose PCa an urgent medical need. In this context, microRNAs (miRNAs) have emerged as potential sources of non-invasive diagnostic biomarkers in several pathologies. Therefore, this study was aimed at assessing for the first time the dysregulation of the whole plasma miRNome in PCa patients and its putative implication in PCa from a personalized perspective (i.e., obesity condition). Plasma miRNome from a discovery cohort (18 controls and 19 PCa patients) was determined using an Affymetrix-miRNA array, showing that the expression of 104 miRNAs was significantly altered, wherein six exhibited a significant receiver operating characteristic (ROC) curve to distinguish between control and PCa patients (area under the curve [AUC] = 1). Then, a systematic validation using an independent cohort (135 controls and 160 PCa patients) demonstrated that miR-107 was the most profoundly altered miRNA in PCa (AUC = 0.75). Moreover, miR-107 levels significantly outperformed the ability of PSA to distinguish between control and PCa patients and correlated with relevant clinical parameters (i.e., PSA). These differences were more pronounced when considering only obese patients (BMI > 30). Interestingly, miR-107 levels were reduced in PCa tissues versus non-tumor tissues (n = 84) and in PCa cell lines versus non-tumor cells. In vitro miR-107 overexpression altered key aggressiveness features in PCa cells (i.e., proliferation, migration, and tumorospheres formation) and modulated the expression of important genes involved in PCa pathophysiology (i.e., lipid metabolism [i.e., FASN] and splicing process). Altogether, miR-107 might represent a novel and useful personalized diagnostic and prognostic biomarker and a potential therapeutic tool in PCa, especially in obese patients.
PB Cell Press
SN 2162-2531
YR 2022
FD 2022-02-10
LK http://hdl.handle.net/10668/22459
UL http://hdl.handle.net/10668/22459
LA en
NO Herrero-Aguayo V, Sáez-Martínez P, Jiménez-Vacas JM, Moreno-Montilla MT, Montero-Hidalgo AJ, Pérez-Gómez JM, et al. Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. Mol Ther Nucleic Acids. 2022 Feb 12;27:1164-1178
NO This work was funded by MINECO/MECD (PID2019-105564RB-I00,FPU16/06190, FPU17/00263, FPU18/02485, FPU18/06009, and PRE2020-094225), University of Córdoba (Programa Operativo FEDERAndalucía: 27416), Junta de Andalucía (BIO-0139, PI-0094-2020,and P20_00442), European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreementno. 847468, and CIBERobn. CIBER is an initiative of Instituto de SaludCarlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain
DS RISalud
RD Apr 6, 2025